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Parvovirus B19 (B19) is a human pathogen transmitted to susceptible individuals via respiratory secretions and
contaminated blood or blood products. B19 levels in pooled plasma of less than 104 genome equivalents/ml may not
be infectious, while those greater than 107/ml are capable of transmitting infection. A World Health Organization
(WHO) B19 DNA international standard has been recently introduced. The purpose of the present work was to
develop a PCR–enzyme-linked immunosorbent assay (PCR-ELISA) calibrated against the WHO B19 DNA inter-
national standard which could easily and reliably detect B19 DNA levels in plasma above 104 IU/ml (6.5  103
genome equivalents/ml). A B19 PCR-ELISA system was developed which uses a dinitrophenylated oligonucleotide
probe to detect immobilized biotinylated amplicons following single-round PCR amplification. The level of B19 DNA
(in international units per milliliter) in individual and pooled plasma specimens was evaluated. Proteinase K
treatment of plasma was found to be sufficient to quantitatively release B19 DNA. The B19 PCR-ELISA had a
sensitivity of detection of 1.6 103 IU/ml B19 DNA and a dynamic range extending from 8 to 1,000 IU of B19 DNA
(equivalent to 1.6 103 to 2 105 IU of B19 DNA/ml). Furthermore, the antibody profile of pooled plasma products
was determined in terms of B19 immunoglobulin G (IgG) (in international units per milliliter). The B19 IgG level
was found to be 64.7 17.5 IU/ml (mean standard deviation). The B19 PCR-ELISA, which is calibrated against
the B19 DNA international standard, may have an application for the rapid screening of plasma minipools for B19
DNA, thereby leading to an improvement in blood product safety.
Parvovirus B19 (B19) is the causative agent of multiple hu-
man diseases, including extensive fetal loss and severe disease
or even death in immunocompromised individuals (20, 22).
Indeed, it can be estimated that upwards of 3,000 pregnancies
per annum may be lost in the European Union and the United
States due to B19 infection, based on an infection rate of 0.1%
and a susceptible cohort of over 3 million pregnancies involv-
ing seronegative females. In Europe, it has been proposed that
15% of immunocompromised patients may succumb to B19
infection per annum, leading to a resultant mortality rate of
7% in this patient cohort (20).
While viral infection can occur though either respiratory
secretions or contaminated blood or blood products, the pre-
cise viral load required to initiate infection is unknown. Con-
sequently, B19 contamination of pooled blood products is of
major significance, primarily due to the high physicochemical
tolerance of B19 to many of the treatments used in plasma
processing allied to the extremely high levels of viremia in
acutely infected, and often asymptomatic, individuals (1012
genome equivalents/ml) (15). These factors combine to
present significant challenges to manufacturers in terms of the
production of B19-free material. Indeed, in the absence of
official regulations to control the safety of blood or blood
products with respect to B19 presence, individual manufactur-
ers have established minipool screening protocols to minimize
B19 contamination (1).
While serological diagnosis of viral infection is now well
standardized and widely available (6, 12), only a limited num-
ber of methods for the extraction and detection of B19 nucleic
acid in single or pooled blood products have, as yet, been
described (1, 3, 11, 19, 24). These assays primarily utilize either
digoxigenin (DIG)-labeled UTP incorporation into newly syn-
thesized amplicons during PCR to facilitate detection or quan-
titative PCR technology such as Taqman chemistry (1, 24).
Despite numerous advantages, application of these systems to
B19 DNA detection in either individual or pooled plasma units
may be limited by irreproducibility of DIG-UTP incorporation,
low sensitivity, and cost factors.
Nonetheless, the availability of these methods—combined
with reliable methods for antibody detection and the introduc-
tion of international-standard preparations for the quantita-
tion of B19 immunoglobulin G (IgG) and, more recently, B19
DNA—is leading to further improvements in the situation in
which manufacturers had depended on the presence of high
levels of B19 IgG alone, in pooled plasma products, as an
indicator of product safety (9, 13, 15, 17). Furthermore, a
recent report has shown that 1 IU of B19 DNA equals 0.65
genome equivalent (1). Despite these advances, a recent study
has highlighted problems with both specimen preparation and
lack of test system standardization for the detection of B19
DNA (17). Moreover, it has been shown that B19 can persist,
at low levels, in immunocompetent individuals for up to 6 to 40
months postinfection (2, 14), implying that ultrasensitive B19
DNA detection is not be suitable for plasma screening due to
detection of viremic, though noninfectious, plasma units. Fur-
thermore, the recent observation that preparations of a pooled
plasma product (Solvent/Detergent Treated Viplas/SD), con-
taining less than 104 genome equivalents/ml, did not lead to
seroconversion in healthy, B19-seronegative volunteers while
under evaluation in a phase IV clinical trial has led to the
consensus that this level of B19 contamination may be a safe
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viral load which is incapable of transmitting B19 infection to
blood product recipients (4).
Here, we report the development of a robust and reliable
microplate detection system for the detection of biotinylated
PCR product using dinitrophenyl (DNP)-labeled probes, in
combination with antibody-enzyme conjugate, for the detec-
tion of B19 DNA in serum or plasma at a sensitivity of 1.6 
103 IU/ml, which may have a utility in plasma screening.
MATERIALS AND METHODS
Specimens. Aliquots of Solvent/Detergent Treated Viplas/SD plasma units
(PS1 to -32), each comprising 5,000 individual donations, were obtained from
Aristides Lazo (VI Technologies, Boston, Mass.) while individual units of par-
vovirus B19-containing plasma (IDS1 to -7) were kind gifts from both Albrecht
Groener and Thomas Weimer (Aventis Behring, Marburg, Germany). The
World Health Organization (WHO) B19 DNA international standard (99/800)
for nucleic acid testing was obtained from the National Institute of Biological
Standards and Control, Potters Bar, Hertfordshire, United Kingdom (18a). This
material, which contains intact B19 virions, consists of lyophilized, pooled plasma
containing a known copy number of 5  105 IU of B19 DNA/vial. All other
specimens which were used to confirm PCR–enzyme-linked immunosorbent
assay (PCR-ELISA) specificity (n  200) were obtained from the Irish Blood
Transfusion Service (Dublin, Ireland). A control plasmid (pB19NS1) containing
the entire B19 NS1 coding region was used as positive control for all PCRs and
was prepared as previously described (8). DNA concentration of pB19NS1 was
computed from A260 measurements and was used in parallel with the B19 DNA
international standard in the establishment of test sensitivity. Note: B19 levels
are expressed in various ways throughout this report, which reflects how levels
were reported in the original publications cited.
Specimen preparation and B19 DNA amplification. Undiluted or diluted
(104 to 1010 in phosphate-buffered saline) specimens (100 l) were digested
with 2 l of proteinase K (20 mg/ml) at 56°C for 1 h, and this was followed by
boiling and centrifugation (13,000  g for 30 min at 4°C) to remove precipitated
protein. Specimens were also extracted with the QiAmp Blood kit (QIAGEN,
Hilden, Germany) as described by the manufacturer (where indicated). DNA
extraction was performed in a laboratory separate from that in which PCR
reagent preparation and nucleic acid amplification were carried out. Template
DNA present in the supernatant (5 l) was added to the following mixture: 10
mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1%(vol/vol) Triton X-100, 2.0 mM MgCl2,
a 200 M concentration of each deoxynucleoside triphosphate (Promega, Mad-
ison, Wis.), 1 M betaine (which enhanced the PCR) (Sigma, Poole, United
Kingdom) (data not shown), a 1.0 M concentration of each oligonucleotide
primer (Table 1) (5, 7) specific for regions within the NS1 coding region of the
B19 genome, and 1.25 U of Taq polymerase (Promega) in a total volume of 50
l. Amplification was as follows: 95°C for 6 min followed by 35 cycles of 95°C for
1 min, 55°C for 1 min, and 72°C for 2 min, terminating in 72°C for 5 min. Ten
microliters of each PCR product was subjected to 1% (wt/vol) agarose gel
electrophoresis with ethidium bromide (0.5 g/ml; Sigma) for 30 min at 100 V.
Amplicon visualization was performed using an Eagle-Eye II gel documentation
system (Stratagene, La Jolla, Calif.).
Microplate preparation and immunoassay format. Microwells (Nunc, Ros-
kilde, Denmark) were coated with streptavidin (2.5 g/ml) and stabilized for 4°C
storage by the addition of 1% (wt/vol) bovine serum albumin in 50 mM sodium
carbonate buffer, pH 9.4. Biotinylated PCR products were diluted 1/20 in 6
SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) to give a final volume
of 100 l, added to microwells coated with streptavidin, and incubated at 37°C
for 30 min. After two washes with phosphate-buffered saline–0.05% (vol/vol)
Tween 20 (PBST), 100 l of 125 mM NaOH–100 mM NaCl was added to the
microwells to dissociate DNA duplex, incubated at room temperature for 10 min,
and washed four times with PBST. Then, 100 l of DNP-labeled oligonucleotide
(Table 1) (100 ng/ml in 6 SSC–0.1% [wt/vol] SDS) was added to the microwells
and incubated for 1 h at 60°C followed by four washes with PBST. Microwells
were then blocked with 2.5% (wt/vol) milk powder in PBST for 1 h at 20°C.
Following removal of the blocking solution, IgG (anti-DNP)-horseradish perox-
idase conjugate was added, and the mixture was incubated at room temperature
for 30 min and washed four times with PBST. Substrate (100 l of tetramethyl-
benzidine) was then added, and the mixture was incubated for 15 min at room
temperature. The reaction was terminated by the addition of 1 N sulfuric acid
and measured spectrophotometrically at 450 and 630 nm (Dynatech MRX).
Serology. B19 IgG and IgM immunoassays were obtained from Biotrin (Dublin,
Ireland) and were used as previously described (12) and in accordance with manu-
facturers’ instructions. Briefly, all immunoassays utilized conformationally intact B19
capsid antigens (VP1 and VP2) for antibody capture, except the Western blot
immunoassay for B19 IgG, which contains denatured B19 capsid proteins (12).
RESULTS
Assay sensitivity. PCR-ELISA sensitivity of detection was
evaluated using dilutions of both the WHO B19 DNA inter-
national standard (99/800) and purified control plasmid
(pB19NS1) containing the entire NS1 gene. ELISA analysis of
the B19 DNA international standard, following proteinase K
extraction and PCR amplification using primers F1 and R1,
facilitated detection of 8 IU of B19 DNA/5 l (1.6  103
IU/ml) (Fig. 1). ELISA evaluation, following extraction using
the Qiagen spin column, resulted in the detection of 40 IU (8
 103 IU/ml) of the B19 DNA international standard (Fig. 1).
These results indicated that proteinase K digestion of the in-
ternational standard resulted in superior detection relative to
that of the spin column-extracted material, and proteinase K
digestion was thus used in subsequent experiments. Figure 1
illustrates a calibration curve, extending over 3 orders of mag-
nitude, generated following PCR amplification of half-log di-
lutions of the B19 DNA international standard which was
subsequently used to compute B19 DNA levels (in interna-
tional units per milliliter) in individual and pooled plasma
specimens. Furthermore, the improvement in PCR-ELISA
sensitivity (8 IU; 1.6  103 IU/ml) over that obtained with
ethidium bromide staining (200 IU; 4  104 IU/ml) following
agarose gel electrophoresis is also evident (Fig. 1).
A sensitivity of detection of 50 copies of the control plasmid
(in 5 l) was determined, which equates to 104 copies/ml.
Similarly to the WHO international standard, the sensitivity of
detection by agarose gel electrophoresis was observed to be 10
times lower (500 copies of control plasmid [105 copies/ml]).
Thus, the ELISA format confers at least a 10-fold increase in
sensitivity over ethidium bromide visualization of amplicons.
TABLE 1. Nucleotide sequences of oligonucleotide primers and their relative positions in the B19 genomea
Primer or probe Gene Position Sequence (5 3 3)
Primers
F1 NS1 1399–1422 Biotin-AATACACTGTGGTTTTATGGGCCG
R1 NS1 1600–1576 CTAAAATGGCTTTTGCAGCTTCTAC
Probe (DNP-Oligo) NS1 1536–1566 (DNP)3-CTTAATAATACCTTCATCCCAGACCACCAA
a The oligonucleotide primers were selected based on previous observations (5, 7). The relative nucleotide positions of the B19 primers are numbered according to
reference 21. Primer F1 was biotinylated at the 5 end to facilitate binding of amplicons to streptavidin-coated microtiter wells. The detection probe was labeled with
three DNP groups at the 5 end to facilitate IgG (anti-DNP)-horseradish peroxidase conjugate binding.
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Specimen evaluation. PCR-ELISA analysis of pooled
plasma specimens (PS1 to -30) detected high levels of viremia
in specimens PS1 to -5 (Fig. 2). All other pooled plasma spec-
imens tested contained either low levels of B19 DNA or levels
which were below the sensitivity of the test system. Subse-
quently, the levels of B19 DNA present in specimens PS1 to -5
were quantified and found to contain between 8.0  107 and
5.0  108 IU of B19 DNA/ml, in addition to B19 IgG levels of
59.5 to 86.5 IU/ml, which were significantly higher than the
immunoassay cutoff (3 IU/ml) (Table 2). No B19 IgM was
detectable in these pools (Table 2) or any other pooled plasma
specimen. All specimens tested were positive for B19 IgG in all
commercial immunoassay systems, including microplate en-
zyme immunoassay and immunofluorescent, Western, and im-
munoblot assays. No specimen reactivity was observed against
denatured VP2 when tested by Western blotting; however, all
specimens were VP1 positive by this method. The B19 IgG
level (mean  standard deviation) in all plasma pools tested
was found to be 64.7  17.5 IU/ml (n  30).
Higher levels of B19 DNA (1.2  109 to 8.0  1011 IU/ml)
were found following evaluation of individual plasma dona-
tions (IDS1 to -7). Significantly, all of these specimens were
B19 IgG negative, and only one contained detectable B19 IgM,
suggesting that all individuals were recently infected with B19
(Table 2). Finally, a pool of 200 serum specimens also tested
negative by the PCR-ELISA, further confirming assay speci-
ficity (specimen/cutoff absorbance ratio, 	1.0).
DISCUSSION
A robust microwell detection system for the high-sensitivity
detection of biotinylated amplicons following extraction and
single-round PCR amplification of parvovirus B19 DNA has
been developed. The overall amplification and detection sys-
tem uses colorimetric detection for specimen visualization, ex-
hibits a sensitivity of detection of 1.6 103 IU of B19 DNA/ml,
is compatible for use with either individual or pooled speci-
mens, and is capable of being automated. Significantly, the
requirement for PCR-dependent incorporation of a detection
moiety (e.g., DIG) is obviated.
Although the use of commercial extraction kits is thought to
reduce the presence of PCR inhibitors, especially for the de-
termination of viral load in plasma pools (18), the data pre-
sented here demonstrate that proteinase K digestion alone is
sufficient to quantitatively release B19 DNA from pooled and
individual plasma specimens treated with citrate. Extraction of
specimen DNA is of paramount importance to ensure quanti-
tative release of target DNA, and a number of methods for
DNA extraction based on efficiency, convenience, reproduc-
ibility, and the presence of inhibitors have been investigated
(25). These authors found that treatment of serum specimens
by rapid heating fulfilled the criteria for routine diagnosis while
other extraction methods, such as lysis treatment and commer-
cial DNA extraction kits, failed to yield higher levels of ex-
tracted DNA based on quantitative PCR results. Our observa-
FIG. 1. PCR-ELISA quantitation using the WHO B19 DNA international standard. Half-log dilutions were extracted by proteinase K (solid
line) or spin column (dashed line) methodologies, subjected to PCR using primers F1 and R1, and analyzed by ELISA. Absorbance at 450 and
630 nm is plotted versus the log amount of B19 DNA. The PCR-ELISA cutoff (0.159) is indicated by the horizontal black line and was calculated
as the mean plus 2 standard deviations [0.107  2(0.026)] following replicate analysis of 20 B19-DNA-negative specimens. A level of 8 IU of B19
DNA was reliably detectable following proteinase K extraction. Amplicon detection by agarose gel electrophoresis detection is also shown (inset).
It can be seen that a minimum of 200 IU of B19 DNA only can be detected by this approach. PD, primer dimer.
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tions for citrate-treated plasma are in agreement with those
found by Zerbini et al. (25), who found that specimen treat-
ment with proteinase K was more efficient for B19 DNA iso-
lation than commercial kits. This observation should be of
significant utility in the large-scale screening of plasma by
blood product manufacturers.
A sensitivity limit of 350 to 3,500 copies of B19 DNA has
been reported (7) when single-round PCR with optimized
primer pairs and ethidium bromide detection has been used
following agarose gel electrophoresis. Using these primers, in
combination with a modified PCR procedure and ELISA-
based amplicon revelation, a minimum of 8 IU of B19 DNA
was detectable in the present study, which represents a signif-
icant improvement over this previous work. Although Durigon
et al. (7) showed that nested PCR improved sensitivity by up to
100-fold, this option is not entirely suitable for large-scale
plasma screening, due to contamination risks.
In the last decade a number of quantitative PCR assays have
been developed to detect B19 DNA in individual serum and
plasma specimens; however, few have directly addressed either
the issue of plasma pool contamination or assay compatibility
with the recently introduced WHO B19 DNA international
standard. Furthermore, these assays may exhibit inappropriate
sensitivity for pooled plasma screening. For instance, Zerbini
et al. (24) reported reliable detection of 60 B19 genome equiv-
alents (1.2  104 /ml) using DIG-labeled PCR product detec-
tion, which is above the B19 level (104 genome equivalents/ml)
thought to represent a noninfectious dose. Conversely, other
authors have reported assay sensitivities of 168 and 100 B19
copies/ml, respectively, the use of which may lead to discarding
viremic, though noninfectious, plasma units (10, 19). Although
dot blot hybridization assays using colorimetric substrates (En-
Vison) have been developed (26) which can detect 3  103
copies (10 fg) of B19 DNA (while the addition of chemilumi-
nescent substrates increased the sensitivity to 6  102 genome
copies [2 fg]), these test formats may not be readily automated
for large-scale specimen processing.
Whole-virus detection using receptor-mediated hemaggluti-
FIG. 2. Qualitative detection of B19 DNA in 30 pooled plasma specimens by PCR-ELISA. Five pools (PS1 to PS5) were found to have high
levels of B19 DNA, the levels of which were subsequently quantified in terms of B19 DNA (in international units per milliliter) (see text). Eleven
pools (PS6 to PS15) appeared to contain low levels of B19 DNA. In 14 pools (PS17 to PS30), any B19 DNA present was below the PCR-ELISA
cutoff of 1.6  103 IU/ml.
TABLE 2. B19 virological and serological status of pooled
plasma and individual specimens
Specimena
Level in plasma
B19 DNA (IU/ml) B19 IgG (IU/ml) B19 IgM (indexb)
PS1 2.2  108 59.5 0.19
PS2 5.0  108 74.0 0.22
PS3 1.6  108 72.0 0.23
PS4 1.2  108 86.5 0.23
PS5 8.0  107 84.0 0.21
IDS1 8.0  1011 0.0 0.13
IDS2 7.0  1011 0.0 0.08
IDS3 2.0  1011 0.0 0.08
IDS4 1.4  1011 0.0 0.26
IDS5 1.2  109 0.0 2.02
IDS6 1.1  1011 0.0 0.24
IDS7 3.2  1011 0.0 0.60
a PS1 to 5, pooled plasma specimens; IDS1 to 7, individual specimens.
b B19 IgM values are expressed as index values (ratio of specimen optical
density to cutoff value optical density). An index of 1.1 implies B19 IgM
positivity.
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nation has been proposed as a strategy for the detection of B19
in plasma (16, 23). However, due to documented false nega-
tivity in the presence of B19 IgG and IgM and the absence of
precise sensitivity of detection in terms of genome equivalents
per milliliter (23), this method does not sufficiently guarantee
blood product safety, in terms of the absence B19 contamina-
tion. The mean plasma B19 IgG level of 75.2 IU/ml observed
in pooled plasma specimens PS1 to -5 strongly suggests that
antibody presence in plasma does not interfere with B19 DNA
extraction or, conversely, that B19 presence in plasma pools
does not interfere with B19 antibody detection in serological
assays. Since the individual donations screened were all B19
IgG negative, it is not possible to predict if free virus interferes
with antibody detection in specimens obtained from individual
donors. However, it should be noted that specimen IDS5,
which was also B19 IgM positive, contained 100 times less B19
DNA than all other individual specimens tested. This obser-
vation may reflect virus diminution as the humoral response is
mounted. The presence and absence of IgG reactivity against
linear epitopes of VP1 and VP2, respectively, are consistent
with results obtained following the serological evaluation of
individual serum samples by Western blot analysis (12). These
results suggest that the potential protective nature of B19 IgG
present in plasma pools primarily comprises antibody reactivity
directed against both conformational and VP1-unique region
epitopes on B19 antigens.
The introduction of a WHO B19 DNA international standard
represents a significant advance in the improvement of blood
product safety and will serve to diminish ambiguity between re-
sults from different organizations currently using either various
assay formats or quantitative terminology to express B19 DNA
levels (i.e., genome equivalents per milliliter, copies per milliliter,
and PCR-detectable units per milliliter [17]). Although there is no
definitive information regarding the precise B19 viral load in
plasma which can transmit infection to recipients, it has been
reported that levels greater than 107 genome equivalents/ml, in
three individual lots of pooled plasma (Solvent/Detergent
Treated Viplas/SD), resulted in B19 seroconversion in 19 recipi-
ents (4). Consequently, there is now an impetus to identify and
remove individual high-titer B19 plasma donations from plasma
pools, and a number of companies have introduced minipool
screening to address this problem.
In conclusion, the currently recommended maximum level
of 104 genome equivalents/ml of B19 DNA in plasma pools as
a safe viral load suggests that the B19 PCR-ELISA presented
here, which is calibrated against the international standard and
has a cutoff of 8 IU of B19 DNA (1.6  103 IU of B19
DNA/ml), has an application for the rapid screening of plasma
donations or minipools for parvovirus B19 DNA, thereby lead-
ing to an improvement in blood product safety.
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